MBX MBX Biosciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1776111 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-80.3%
TTM EPS YoY-139.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-33.7%
ROA-32.2%
ROIC (approx.)-53.3%
Asset turnover—
Leverage & solvency
Liabilities / assets5.5%
Debt / equity0.00x
Current ratio19.58x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.66x
Accruals ratio-10.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $32.05M | $30.98M | $18.47M | $19.76M | $19.27M | $17.72M | $22.41M | $15.22M |
| SG&A expense | $34.30M | $9.95M | $8.79M | $6.04M | $4.66M | $4.08M | $4.12M | $3.39M |
| Operating income | -$66.34M | -$40.93M | -$27.27M | -$25.80M | -$23.93M | -$21.80M | -$26.53M | -$18.61M |
| Net income | -$62.42M | -$37.09M | -$23.52M | -$22.06M | -$21.62M | -$19.41M | -$23.88M | -$15.59M |
| EBITDA | -$66.24M | -$40.83M | -$27.20M | -$25.73M | -$23.83M | -$21.70M | -$26.45M | -$18.55M |
| EPS (basic) | -1.29 | -0.78 | -0.50 | — | -0.63 | -0.58 | -0.71 | — |
| EPS (diluted) | -1.29 | -0.78 | -0.50 | — | -0.63 | -0.58 | -0.71 | — |
| Weighted avg. shares (diluted) | 48.56M | 47.70M | 46.58M | — | 34.20M | 33.45M | 33.41M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $161.69M | $54.12M | $45.21M | $75.29M | $223.12M | $39.78M | $29.90M | $49.35M |
| Short-term investments | $319.90M | $364.46M | $394.76M | $298.42M | $168.55M | $185.12M | $210.88M | $212.80M |
| Current assets | $492.76M | $427.86M | $448.54M | $381.54M | $397.50M | $229.19M | $244.28M | $267.29M |
| PP&E, net | $5.00M | $4.66M | $3.13M | $2.73M | $2.00M | $1.73M | $1.51M | $1.08M |
| Total assets | $500.62M | $435.91M | $452.70M | $385.14M | $400.08M | $231.52M | $245.93M | $268.54M |
| Current liabilities | $25.17M | $23.66M | $14.57M | $15.49M | $12.06M | $11.76M | $10.48M | $11.05M |
| Total liabilities | $27.67M | $26.37M | $14.95M | $15.92M | $12.54M | $12.28M | $10.50M | $11.09M |
| Shareholders' equity | $472.95M | $409.54M | $437.76M | $369.22M | $387.54M | $219.24M | $235.42M | $257.44M |
| Shares outstanding | 49.64M | 47.95M | 47.57M | 44.93M | 44.72M | 33.59M | 33.42M | 33.42M |
| Cash flow statement | ||||||||
| Operating cash flow | -$34.88M | -$22.62M | -$20.21M | -$18.30M | -$21.54M | -$17.43M | -$22.68M | -$16.04M |
| Capital expenditure | $1.19M | $901,000 | $437,000 | $793,000 | $399,000 | $707,000 | $30,000 | $92,000 |
| Free cash flow | -$36.07M | -$23.52M | -$20.64M | -$19.09M | -$21.93M | -$18.14M | -$22.71M | -$16.13M |
| Investing cash flow | $42.83M | $29.21M | -$97.10M | -$129.97M | $17.06M | $25.99M | $3.23M | -$67.34M |
| Financing cash flow | $99.61M | $2.32M | $87.44M | $438,000 | $187.82M | $1.33M | $4,000 | -$132,000 |
| Depreciation & amortization | $100,000 | $100,000 | $64,000 | $60,000 | $100,000 | $100,000 | $77,000 | $58,000 |
| Stock-based compensation | $27.55M | $6.06M | $5.48M | $2.66M | $2.25M | $1.94M | $1.84M | $1.49M |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.